Q4 2022 vs. Q4 2021 Restated Net Sales New Segment Presentation Less: Impact Less: Impact of Foreign of Recent Q4 Q4 As Reported Currency Operational Acquisitions / Organic (in millions) 2022 2021 Basis Fluctuations Basis Divestitures Basis ENDOSCOPY $ 571 $ 558 2.4 % (5.1) % 7.4 % — % 7.4 % UROLOGY 477 441 8.2 % (3.6) % 11.8 % — % 11.8 % NEUROMODULATION 249 244 2.1 % (2.8) % 4.9 % — % 4.9 % MEDSURG 1,297 1,243 4.4 % (4.1) % 8.5 % — % 8.5 % ICTx 561 575 (2.4) % (7.6) % 5.2 % — % 5.2 % WATCHMAN 280 233 20.5 % (1.4) % 21.9 % — % 21.9 % CARDIAC RHYTHM MANAGEMENT 521 514 1.3 % (4.5) % 5.8 % — % 5.8 % ELECTROPHYSIOLOGY 167 100 66.7 % (9.8) % 76.4 % 51.4 % 25.1 % CARDIOLOGY 1,529 1,422 7.5 % (5.6) % 13.2 % 3.6 % 9.6 % PERIPHERAL INTERVENTIONS 476 462 3.0 % (5.8) % 8.8 % — % 8.8 % CARDIOVASCULAR 2,005 1,884 6.4 % (5.7) % 12.1 % 2.7 % 9.4 % 3,302 3,127 5.6 % (5.0) % 10.7 % 1.6 % 9.0 % † OTHER (60) — (100.0) % — % (100.0) % — % (100.0) % WORLDWIDE NET SALES $ 3,242 $ 3,127 3.7 % (5.0) % 8.7 % 1.6 % 7.1 % 28 Q4 2022 Financial & Operational Highlights | February 1, 2023